Search for content, post, videos

New Director of Biopharmaceuticals and ATMPs at NDA

Paula Salmikangas

Dr Paula Salmikangas, former chair of EMA Committee for Advanced Therapies (CAT), has joined the NDA Advisory Board as Director of Biopharmaceuticals and ATMPs.

Dr Salmikangas has a Ph.D. in muscle cell biology and extensive knowledge in biological medicinal products, especially advanced therapy medicinal products and CMC aspects of biopharmaceuticals. Her main research has focused on cell and molecular biology of various inherited diseases. Since 2006, she has been an Adjunct Professor of Biochemistry for the University of Helsinki.  She is joining NDA from her position as a Research Professor at the Finnish Medicines Agency (2003-2017) and as a member of the EMA Committee for Advanced Therapies (CAT) from 2009 to 2017 and as the Chair of the CAT 2014-2017. Dr Salmikangas has also been the Chair of EMA Cell Products Working Party and a member of the Biologicals Working party.

Dr Werner Van den Eynde, Vice President NDA Advisory Board, commented on the appointment: “The NDA Advisory Board is one of a kind – no other professional body comes as close to reflecting the current opinions and practices of the world’s regulatory and reimbursement agencies. I am very excited to welcome Dr Paula Salmikangas on board. With her experience in and in-depth knowledge of biopharmaceuticals and advanced therapies she will be able to add tremendous value to clients in these areas and help them to make new and promising medicines available to patients.”

Dr Salmikangas is the second appointment in a short time frame to the NDA Advisory Board. This follows on the back of the company’s expansions in the US, with the establishment of offices in both Boston, MA, and Princeton, NJ.

Johan Strömquist, CEO of NDA Group, commented on the appointment: “It is becoming increasingly important for pharmaceutical companies to work with partners that truly understand the science of the technology, the therapeutic area and the regulatory and payer environment, to ensure that their products reach the intended patients with minimum delay. At NDA we expand both to get closer to our clients, many who are based in the United States, and to ensure we continue to be at the forefront of technical and medical development.”

Leave a Reply

Your email address will not be published. Required fields are marked *

5 × five =